Navigation Links
GranuFlo Lawsuits News: Missouri Federal Court Returns Multi-Plaintiff Case to State Court, Rottenstein Law Group LLP Reports
Date:1/15/2014

(PRWEB) January 15, 2014

A lawsuit against Fresenius Medical Care, the manufacturer of GranuFlo, brought by 74 plaintiffs (or their estates, in the cases of those who died from their injuries), has been returned to state court by the federal court to which the defendant had previously removed the matter, according to documents in Agnew v. Fresenius (no. 4:13-2468; United States District Court for the Eastern District of Missouri). A magistrate judge ruled that the federal court does not have proper jurisdiction to hear the case, according to the January 9 remand order.

The plaintiffs, from 27 different states, seek monetary relief for injuries or deaths allegedly resulting from use of GranuFlo dialysis products designed, manufactured, tested, promoted, and sold by Fresenius, according to documents filed in the case. The Rottenstein Law Group LLP, which represents clients in GranuFlo dialysis injury lawsuits, maintains a website at http://www.granuflo-lawsuit.net that features information on GranuFlo side effects and lawsuits.

In June 2012 the U.S. Food and Drug Administration issued a Class 1 Recall after learning about the alleged adverse side effects involving the heart.* The FDA had originally approved the drug for distribution in 2003.

“That the resolution of this matter was delayed by a procedural tacticc ultimately undone by the federal court is unfortunate,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP., ”but at least now, with the remand, the Missouri state court can get to the substance of the case.”

The Rottenstein Law Group LLP encourages those who believe they have suffered from the alleged side effects of GranuFlo to read the frequently asked questions and answers about the drug to learn more about its side effects and how to file a lawsuit.

*fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm305630.htm

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
100 Merrick Road
Suite 226W
Rockville Centre, NY 11570
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
plus.google.com/106070664376281033016

Read the full story at http://www.prweb.com/releases/2014/01/prweb11490108.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. GranuFlo Lawsuit Consolidation Supported by Fresenius Medical Care, Bernstein Liebhard LLP Reports
2. GranuFlo Recall Website Launched By Hissey Kientz, LLP Law Firm
3. d'Oliveira & Associates Releases Fresenius Infographic about the FDA Recall of NaturaLyte and GranuFlo
4. GranuFlo Lawsuits Filed in Wake of GranuFlo and NaturaLyte Recall Mount in State and Federal Courts, Bernstein Liebhard LLP Reports
5. The National Plaintiff’s Law Firm of Baron and Budd Handling Granuflo Recall Lawsuits
6. New Granuflo Cardiac Arrest Lawsuit: Now, AttorneyOne Can Provide Advice
7. GranuFlo Lawsuit News: Bernstein Liebhard LLP Reports on Growing Litigation Surrounding GranuFlo Recall
8. Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama
9. GranuFlo Lawsuits Moving Forward in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports
10. GranuFlo Lawsuits Move Forward, as Bernstein Liebhard Notes Issuance of New Order in Federal GranuFlo Recall Litigation
11. GranuFlo Lawsuit News: W.Va. Man’s Lawsuit Goes to Federal Court, Rottenstein Law Group LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , ... January 24, 2017 , ... “Mysteries Revealed On ... be a mysterious phenomenon is available to all Christians. “Mysteries Revealed On Speaking In ... of “U Beautiful Creation,” a Christian-based talk show located in Michigan. , “We ...
(Date:1/24/2017)... ... January 24, 2017 , ... Attention ... article suggests that autologous fat grafting—taking one’s own fat and putting ... without breast implants. , Cosmetic Surgeon and Medical Director of MilfordMD Cosmetic ...
(Date:1/24/2017)... ... 23, 2017 , ... OSF Ventures, the corporate investment arm ... platform headquartered in Silicon Valley that connects startups to corporations and invests in ... three-year agreement to be a corporate sponsor of Plug and Play’s program for ...
(Date:1/24/2017)... ... January 23, 2017 , ... Texas Home ... acquisitions of two personal care service companies: Padre Home Health in Corpus Christi, ... 1, 2017. , Well regarded in their respective markets, these two agencies align ...
(Date:1/24/2017)... Santa Clara, CA (PRWEB) , ... January 23, ... ... technology, announces the launch of a new plugin that allows sleep centers to ... Somnoware Sleep Device Interface (SDI)—is a thin client browser plugin is quickly installed ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... 23, 2017 ArisGlobal, a leading ... announces agClinical 3.3, the latest version of its comprehensive ... science organizations to confidently and efficiently meet new compliance ... the electronic trial master file so that compliance is ... ...
(Date:1/23/2017)... 2017  HOPE BIOSCIENCES announced today that it ... commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) through a licensing ... nuc -Gemcitabine consists of Antisoma,s ... found on many cancer cells, and dFdCMP, an ... conjugates) or SMDCs (small molecule drug conjugates), which ...
(Date:1/23/2017)... 23, 2017  Therabron Therapeutics, Inc., a clinical-stage ... in respiratory care, today announced that the European ... has granted Orphan Drug Designation for Therabron,s CG367 ... Syndrome (BOS).  "We are pleased to ... to treat patients diagnosed with BOS following lung ...
Breaking Medicine Technology: